Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete cancer regressions and immunological memory in animal models, Indaptus plans to advance human clinical evaluation of the combination of BeiGene’s anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDP:
- Indaptus initiates unrestricted enrollment on patients on Decoy20 weekly dosing
- Indaptus Therapeutics CSO to speak on webinar about cancer immunotherapy
- Indaptus Therapeutics files to sell 1.64M shares of common stock for holders
- Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose